nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—Septicemia—Cyclosporine—focal segmental glomerulosclerosis	0.0256	0.0353	CcSEcCtD
Alitretinoin—RXRG—Adipogenesis—ZMPSTE24—focal segmental glomerulosclerosis	0.0218	0.0798	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—ZMPSTE24—focal segmental glomerulosclerosis	0.0205	0.075	CbGpPWpGaD
Alitretinoin—Benign intracranial hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.0197	0.0273	CcSEcCtD
Alitretinoin—Skin infection—Cyclosporine—focal segmental glomerulosclerosis	0.0192	0.0266	CcSEcCtD
Alitretinoin—Papilloedema—Cyclosporine—focal segmental glomerulosclerosis	0.0182	0.0252	CcSEcCtD
Alitretinoin—Renal tubular necrosis—Cyclosporine—focal segmental glomerulosclerosis	0.0162	0.0225	CcSEcCtD
Alitretinoin—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.0126	0.0174	CcSEcCtD
Alitretinoin—Bacterial infection—Cyclosporine—focal segmental glomerulosclerosis	0.0126	0.0174	CcSEcCtD
Alitretinoin—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.0118	0.0164	CcSEcCtD
Alitretinoin—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0107	0.0149	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—ZMPSTE24—focal segmental glomerulosclerosis	0.0107	0.0391	CbGpPWpGaD
Alitretinoin—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0101	0.014	CcSEcCtD
Alitretinoin—Hirsutism—Cyclosporine—focal segmental glomerulosclerosis	0.00998	0.0138	CcSEcCtD
Alitretinoin—CRABP1—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00987	0.0362	CbGpPWpGaD
Alitretinoin—CRABP2—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00987	0.0362	CbGpPWpGaD
Alitretinoin—Gastrointestinal symptom NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00987	0.0136	CcSEcCtD
Alitretinoin—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00943	0.013	CcSEcCtD
Alitretinoin—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.00943	0.013	CcSEcCtD
Alitretinoin—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00923	0.0128	CcSEcCtD
Alitretinoin—Encephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00904	0.0125	CcSEcCtD
Alitretinoin—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00895	0.0124	CcSEcCtD
Alitretinoin—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00886	0.0122	CcSEcCtD
Alitretinoin—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00851	0.0118	CcSEcCtD
Alitretinoin—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.0082	0.0113	CcSEcCtD
Alitretinoin—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00805	0.0111	CcSEcCtD
Alitretinoin—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00751	0.0104	CcSEcCtD
Alitretinoin—Coagulopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00745	0.0103	CcSEcCtD
Alitretinoin—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00745	0.0103	CcSEcCtD
Alitretinoin—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00739	0.0102	CcSEcCtD
Alitretinoin—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00739	0.0102	CcSEcCtD
Alitretinoin—Tingling sensation—Cyclosporine—focal segmental glomerulosclerosis	0.00722	0.00998	CcSEcCtD
Alitretinoin—Stinging—Cyclosporine—focal segmental glomerulosclerosis	0.00716	0.0099	CcSEcCtD
Alitretinoin—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.0069	0.00953	CcSEcCtD
Alitretinoin—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.0068	0.00939	CcSEcCtD
Alitretinoin—RARG—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00667	0.0244	CbGpPWpGaD
Alitretinoin—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.00913	CcSEcCtD
Alitretinoin—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00656	0.00906	CcSEcCtD
Alitretinoin—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00647	0.00894	CcSEcCtD
Alitretinoin—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00642	0.00888	CcSEcCtD
Alitretinoin—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00638	0.00882	CcSEcCtD
Alitretinoin—Lacrimation increased—Cyclosporine—focal segmental glomerulosclerosis	0.0063	0.0087	CcSEcCtD
Alitretinoin—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.0063	0.0087	CcSEcCtD
Alitretinoin—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00625	0.00864	CcSEcCtD
Alitretinoin—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00621	0.00859	CcSEcCtD
Alitretinoin—RXRG—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.0061	0.0223	CbGpPWpGaD
Alitretinoin—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.0061	0.00842	CcSEcCtD
Alitretinoin—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.0061	0.00842	CcSEcCtD
Alitretinoin—RARB—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00598	0.0219	CbGpPWpGaD
Alitretinoin—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00591	0.00817	CcSEcCtD
Alitretinoin—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—CTGF—focal segmental glomerulosclerosis	0.00591	0.0216	CbGpPWpGaD
Alitretinoin—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.0058	0.00802	CcSEcCtD
Alitretinoin—RXRB—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00573	0.021	CbGpPWpGaD
Alitretinoin—RARA—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00573	0.021	CbGpPWpGaD
Alitretinoin—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.00554	0.00766	CcSEcCtD
Alitretinoin—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.0053	0.00733	CcSEcCtD
Alitretinoin—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.0053	0.00733	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00505	0.0185	CbGpPWpGaD
Alitretinoin—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00504	0.00696	CcSEcCtD
Alitretinoin—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00494	0.00682	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00484	0.0177	CbGpPWpGaD
Alitretinoin—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00484	0.00669	CcSEcCtD
Alitretinoin—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00471	0.00651	CcSEcCtD
Alitretinoin—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00469	0.00648	CcSEcCtD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.00453	0.0166	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.00453	0.0166	CbGpPWpGaD
Alitretinoin—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00444	0.00614	CcSEcCtD
Alitretinoin—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00443	0.00612	CcSEcCtD
Alitretinoin—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00441	0.00609	CcSEcCtD
Alitretinoin—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00433	0.00599	CcSEcCtD
Alitretinoin—RXRA—Recycling of bile acids and salts—ALB—focal segmental glomerulosclerosis	0.00433	0.0159	CbGpPWpGaD
Alitretinoin—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00432	0.00596	CcSEcCtD
Alitretinoin—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.0043	0.00594	CcSEcCtD
Alitretinoin—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00421	0.00582	CcSEcCtD
Alitretinoin—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.00573	CcSEcCtD
Alitretinoin—RARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00414	0.0152	CbGpPWpGaD
Alitretinoin—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00399	0.00551	CcSEcCtD
Alitretinoin—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.00545	CcSEcCtD
Alitretinoin—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00386	0.00534	CcSEcCtD
Alitretinoin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00379	0.0139	CbGpPWpGaD
Alitretinoin—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.00515	CcSEcCtD
Alitretinoin—RARB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00371	0.0136	CbGpPWpGaD
Alitretinoin—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00366	0.00506	CcSEcCtD
Alitretinoin—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00364	0.00503	CcSEcCtD
Alitretinoin—Acitretin—ALB—focal segmental glomerulosclerosis	0.00359	1	CrCbGaD
Alitretinoin—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00358	0.00495	CcSEcCtD
Alitretinoin—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.00493	CcSEcCtD
Alitretinoin—RARA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00356	0.013	CbGpPWpGaD
Alitretinoin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00356	0.013	CbGpPWpGaD
Alitretinoin—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.00355	0.0049	CcSEcCtD
Alitretinoin—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00349	0.00482	CcSEcCtD
Alitretinoin—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.0047	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00338	0.00468	CcSEcCtD
Alitretinoin—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00336	0.00465	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.00334	0.0122	CbGpPWpGaD
Alitretinoin—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00331	0.00458	CcSEcCtD
Alitretinoin—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00455	CcSEcCtD
Alitretinoin—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.00451	CcSEcCtD
Alitretinoin—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.00449	CcSEcCtD
Alitretinoin—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00325	0.00449	CcSEcCtD
Alitretinoin—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00447	CcSEcCtD
Alitretinoin—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.0032	0.00442	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.0032	0.0117	CbGpPWpGaD
Alitretinoin—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00319	0.00441	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.0044	CcSEcCtD
Alitretinoin—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.0044	CcSEcCtD
Alitretinoin—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00316	0.00437	CcSEcCtD
Alitretinoin—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00316	0.00436	CcSEcCtD
Alitretinoin—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00316	0.00436	CcSEcCtD
Alitretinoin—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.00428	CcSEcCtD
Alitretinoin—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00306	0.00423	CcSEcCtD
Alitretinoin—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00305	0.00421	CcSEcCtD
Alitretinoin—RXRA—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.00299	0.011	CbGpPWpGaD
Alitretinoin—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00293	0.00405	CcSEcCtD
Alitretinoin—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00291	0.00403	CcSEcCtD
Alitretinoin—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00291	0.00403	CcSEcCtD
Alitretinoin—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.0029	0.00401	CcSEcCtD
Alitretinoin—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.004	CcSEcCtD
Alitretinoin—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00288	0.00398	CcSEcCtD
Alitretinoin—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00286	0.00395	CcSEcCtD
Alitretinoin—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00281	0.00388	CcSEcCtD
Alitretinoin—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00272	0.00375	CcSEcCtD
Alitretinoin—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.0027	0.00374	CcSEcCtD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.00269	0.00984	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.00269	0.00984	CbGpPWpGaD
Alitretinoin—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00264	0.00365	CcSEcCtD
Alitretinoin—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00261	0.00361	CcSEcCtD
Alitretinoin—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.0026	0.0036	CcSEcCtD
Alitretinoin—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00356	CcSEcCtD
Alitretinoin—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00255	0.00353	CcSEcCtD
Alitretinoin—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00254	0.00351	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00252	0.00925	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—LPL—focal segmental glomerulosclerosis	0.00252	0.00922	CbGpPWpGaD
Alitretinoin—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00345	CcSEcCtD
Alitretinoin—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00344	CcSEcCtD
Alitretinoin—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.0034	CcSEcCtD
Alitretinoin—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.0033	CcSEcCtD
Alitretinoin—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00238	0.00328	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—LPL—focal segmental glomerulosclerosis	0.00237	0.00867	CbGpPWpGaD
Alitretinoin—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00325	CcSEcCtD
Alitretinoin—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.00324	CcSEcCtD
Alitretinoin—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00322	CcSEcCtD
Alitretinoin—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00316	CcSEcCtD
Alitretinoin—RXRA—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	0.00226	0.00829	CbGpPWpGaD
Alitretinoin—RXRA—BMAL1:CLOCK,NPAS2 activates circadian gene expression—SERPINE1—focal segmental glomerulosclerosis	0.00222	0.00812	CbGpPWpGaD
Alitretinoin—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00221	0.00306	CcSEcCtD
Alitretinoin—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.0022	0.00304	CcSEcCtD
Alitretinoin—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00219	0.00303	CcSEcCtD
Alitretinoin—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.00298	CcSEcCtD
Alitretinoin—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.00298	CcSEcCtD
Alitretinoin—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.00298	CcSEcCtD
Alitretinoin—RXRG—Adipogenesis—AGT—focal segmental glomerulosclerosis	0.00215	0.00789	CbGpPWpGaD
Alitretinoin—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00215	0.00297	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00214	0.00296	CcSEcCtD
Alitretinoin—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00213	0.00295	CcSEcCtD
Alitretinoin—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00211	0.00292	CcSEcCtD
Alitretinoin—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.00288	CcSEcCtD
Alitretinoin—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00286	CcSEcCtD
Alitretinoin—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00286	CcSEcCtD
Alitretinoin—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00206	0.00284	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00205	0.00751	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00205	0.00751	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—CTGF—focal segmental glomerulosclerosis	0.00203	0.00745	CbGpPWpGaD
Alitretinoin—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00203	0.00281	CcSEcCtD
Alitretinoin—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00203	0.0028	CcSEcCtD
Alitretinoin—RARA—Adipogenesis—AGT—focal segmental glomerulosclerosis	0.00202	0.00742	CbGpPWpGaD
Alitretinoin—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00201	0.00278	CcSEcCtD
Alitretinoin—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00277	CcSEcCtD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—focal segmental glomerulosclerosis	0.00199	0.00729	CbGpPWpGaD
Alitretinoin—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00273	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.00261	CcSEcCtD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—LPL—focal segmental glomerulosclerosis	0.00187	0.00687	CbGpPWpGaD
Alitretinoin—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00259	CcSEcCtD
Alitretinoin—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.00257	CcSEcCtD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.00186	0.0068	CbGpPWpGaD
Alitretinoin—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.00255	CcSEcCtD
Alitretinoin—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.00254	CcSEcCtD
Alitretinoin—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.00252	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.0018	0.00661	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.0018	0.00661	CbGpPWpGaD
Alitretinoin—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.00249	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00247	CcSEcCtD
Alitretinoin—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00247	CcSEcCtD
Alitretinoin—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.00245	CcSEcCtD
Alitretinoin—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.00245	CcSEcCtD
Alitretinoin—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00236	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00234	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.00169	0.00618	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.00167	0.00611	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—SERPINE1—focal segmental glomerulosclerosis	0.00166	0.00607	CbGpPWpGaD
Alitretinoin—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00227	CcSEcCtD
Alitretinoin—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00226	CcSEcCtD
Alitretinoin—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00226	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.00162	0.00593	CbGpPWpGaD
Alitretinoin—RXRA—Circadian Clock—SERPINE1—focal segmental glomerulosclerosis	0.00161	0.00592	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.0016	0.00585	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—SERPINE1—focal segmental glomerulosclerosis	0.00156	0.0057	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00211	CcSEcCtD
Alitretinoin—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00149	0.00205	CcSEcCtD
Alitretinoin—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.00202	CcSEcCtD
Alitretinoin—RARG—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.00145	0.00531	CbGpPWpGaD
Alitretinoin—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00196	CcSEcCtD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.00137	0.00503	CbGpPWpGaD
Alitretinoin—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00189	CcSEcCtD
Alitretinoin—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.00135	0.00493	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.00133	0.00486	CbGpPWpGaD
Alitretinoin—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.00182	CcSEcCtD
Alitretinoin—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.0018	CcSEcCtD
Alitretinoin—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.0018	CcSEcCtD
Alitretinoin—RARB—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.0013	0.00476	CbGpPWpGaD
Alitretinoin—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00179	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.00125	0.00458	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.00125	0.00458	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.00125	0.00457	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.00125	0.00457	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—LPL—focal segmental glomerulosclerosis	0.00123	0.00452	CbGpPWpGaD
Alitretinoin—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.0017	CcSEcCtD
Alitretinoin—RXRA—PPARA activates gene expression—AGT—focal segmental glomerulosclerosis	0.00121	0.00442	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.00118	0.00433	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—focal segmental glomerulosclerosis	0.00118	0.00432	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.00108	0.00397	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.00107	0.00392	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.00107	0.00392	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—AGT—focal segmental glomerulosclerosis	0.00105	0.00387	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—TGFB1—focal segmental glomerulosclerosis	0.00104	0.00383	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00101	0.0037	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—TGFB1—focal segmental glomerulosclerosis	0.000982	0.0036	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000916	0.00336	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000912	0.00334	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000912	0.00334	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000903	0.00331	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000892	0.00327	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000874	0.0032	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000874	0.0032	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000843	0.00309	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000821	0.00301	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000821	0.00301	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.000813	0.00298	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—SERPINE1—focal segmental glomerulosclerosis	0.000811	0.00297	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000803	0.00294	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000803	0.00294	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—focal segmental glomerulosclerosis	0.000778	0.00285	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000753	0.00276	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000748	0.00274	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00074	0.00271	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.00074	0.00271	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000722	0.00265	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000698	0.00256	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000674	0.00247	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000666	0.00244	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000662	0.00243	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000661	0.00242	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.00065	0.00238	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000638	0.00234	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000626	0.00229	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.00062	0.00227	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000604	0.00221	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.0006	0.0022	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.0006	0.0022	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000593	0.00217	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000572	0.0021	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000568	0.00208	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000568	0.00208	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000557	0.00204	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—LPL—focal segmental glomerulosclerosis	0.000557	0.00204	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—LPL—focal segmental glomerulosclerosis	0.000557	0.00204	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000546	0.002	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—TGFB1—focal segmental glomerulosclerosis	0.000512	0.00188	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—AGT—focal segmental glomerulosclerosis	0.000476	0.00175	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AGT—focal segmental glomerulosclerosis	0.000476	0.00175	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000467	0.00171	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000424	0.00155	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000378	0.00139	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000376	0.00138	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000375	0.00137	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ALB—focal segmental glomerulosclerosis	0.000366	0.00134	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ALB—focal segmental glomerulosclerosis	0.000366	0.00134	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000337	0.00123	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000324	0.00119	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000318	0.00117	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CTGF—focal segmental glomerulosclerosis	0.000313	0.00115	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	0.000305	0.00112	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000296	0.00109	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000291	0.00107	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000285	0.00105	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000284	0.00104	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000276	0.00101	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000274	0.001	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000274	0.001	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	0.000248	0.000911	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000243	0.000891	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000236	0.000866	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000229	0.000838	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000224	0.000821	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP9—focal segmental glomerulosclerosis	0.000214	0.000783	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000198	0.000725	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	0.000176	0.000645	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000174	0.000638	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—LPL—focal segmental glomerulosclerosis	0.000169	0.000618	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.00015	0.000551	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AGT—focal segmental glomerulosclerosis	0.000144	0.000528	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	0.000143	0.000523	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000121	0.000443	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ALB—focal segmental glomerulosclerosis	0.000111	0.000406	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.00011	0.000405	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000103	0.000379	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	9.72e-05	0.000356	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	9.44e-05	0.000346	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.95e-05	0.000328	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	8.81e-05	0.000323	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7.93e-05	0.000291	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	7.76e-05	0.000284	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.15e-05	0.000262	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	6.74e-05	0.000247	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	5.76e-05	0.000211	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	5.38e-05	0.000197	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	4.6e-05	0.000169	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	4.42e-05	0.000162	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	3.53e-05	0.000129	CbGpPWpGaD
